mdi-book-open-variant Impressum mdi-help Hilfe / Anleitung mdi-printer Webseite ausdrucken mdi-bookmark Bookmark der Webseite speichern mdi-magnify Suche & Index Wirkstoffe mdi-sitemap Sitemap CliniPharm/CliniTox-Webserver mdi-home Startseite CliniPharm/CliniTox-Webserver mdi-email Beratungsdienst: Email / Post / Fax / Telefon

Belloli C, Ceci L, Montesissa C, De Natale G, Marcogrigiano G et al
Disposition of antimony and aminosidine in dogs after administration separately and together: Implications for therapy of leishmaniasis.

Res Vet Sci, 58(2): 123-127, 1995
ISSN: 0034-5288 Research in Veterinary Science (PubMed)

Abstract
The pharmacokinetic behaviour of aminosidine (15 mg kg-1) and antimony (25.65 mg kg-1 as N-methylglucamine antimoniate), administered subcutaneously either separately or together was studied on four dogs. The results demonstrated that antimony (sb) did not significantly modify the kinetics of aminosidine (AM) but that the kinetic behaviour of the metal was markedly influenced by the antibiotic, as shown by the differences in mean residence time (MRT), elimination rate constant (Kel) and area under the curve (AUC) with and without the antibiotic (MRT (Sb)] = 243.8 +/- 29.5 minutes, MRT([sb+AM]) = 1067.9 +/- 199.2 minutes; Kel([Sb]) = 0 008 +/- 0.001 min-1, Kel(Sb+AM) = 0.0015 +/- 0.00013 min-1; AUC[Sb] = 21,024 6 +/- 4448.5 mug min ml-1, AUC([Sb+AM]) = 130,478.5 +/- 30,481.7 mug min ml-1). The persistence of high serum concentrations of antimony when it was administered with aminosidine suggests that the therapeutic doses commonly used should be reduced and that the interval between administration should be increased to avoid the metal reaching toxic concentrations.

© {{ new Date().getFullYear() }} - Institut für Veterinärpharmakologie und ‑toxikologie

Es kann keinerlei Haftung für Ansprüche übernommen werden, die aus dieser Webseite erwachsen könnten.